Quarterly report pursuant to Section 13 or 15(d)

Share-Based Compensation

v3.22.2
Share-Based Compensation
 6 Months Ended
Jun. 30, 2022
Share-Based Payment Arrangement [Abstract]  
Share-Based Compensation

7. Share-Based Compensation

The Company has share-based compensation plans, which are more fully described in Note 9, Share-Based Compensation, to the Consolidated Financial Statements included in the 2021 10-K. During the six months ended June 30, 2022, the Company granted restricted stock units subject to service conditions and restricted stock units subject to service and performance conditions.

Share-based compensation expense amounted to $13.7 million and $14.6 million for the three months ended June 30, 2022 and 2021, respectively, and $26.1 million and $27.9 million for the six months ended June 30, 2022 and 2021, respectively. As of June 30, 2022, the total unrecognized compensation cost related to all non-vested stock awards was $100.0 million and the related weighted-average period over which it is expected to be recognized is approximately 1.8 years.

The following table summarizes the activity for all stock appreciation rights, or SARs, under the Company’s share-based compensation plans for the six months ended June 30, 2022:

 

 

 

Number of Awards

 

 

Weighted-Average Exercise Price Per Award

 

 

Weighted-Average Remaining Contractual Term

 

Aggregate Intrinsic Value(1)

 

 

 

(in thousands)

 

 

 

 

 

 

 

(in millions)

 

Outstanding as of December 31, 2021(2)

 

 

2,622

 

 

$

27.10

 

 

3.8 years

 

$

36.3

 

Granted

 

 

—

 

 

$

—

 

 

 

 

 

 

Exercised

 

 

(37

)

 

$

20.57

 

 

 

 

 

 

Forfeited

 

 

(176

)

 

$

23.17

 

 

 

 

 

 

Outstanding as of June 30, 2022(2)

 

 

2,409

 

 

$

27.49

 

 

3.5 years

 

$

2.5

 

Exercisable as of June 30, 2022(2)

 

 

2,409

 

 

$

27.49

 

 

3.5 years

 

$

2.5

 

Vested and expected to vest as of June 30, 2022

 

 

2,409

 

 

$

27.49

 

 

3.5 years

 

$

2.5

 

 

(1)
The intrinsic value is the amount by which the current market value of the underlying stock exceeds the exercise price of the SARs.
(2)
Includes 0.8 million performance condition SARs.

There were no SARs granted during the three and six months ended June 30, 2022 and 2021. The total intrinsic value of SARs exercised during the three months ended June 30, 2022 and 2021 was $0.1 million and $10.3 million, respectively. The total intrinsic value of SARs exercised during the six months ended June 30, 2022 and 2021 was $0.4 million and $24.1 million, respectively.

The following table summarizes the activities for all restricted stock units under the Company’s share-based compensation plans for the six months ended June 30, 2022:

 

 

 

Number of Shares

 

 

Weighted-Average Grant Date Fair Value Per Share

 

 

 

(in thousands)

 

 

 

 

Outstanding and nonvested as of December 31, 2021(1)

 

 

3,400

 

 

$

45.26

 

Granted(2)

 

 

2,069

 

 

$

36.08

 

Vested

 

 

(792

)

 

$

48.75

 

Forfeited(3)

 

 

(260

)

 

$

43.28

 

Outstanding and nonvested as of June 30, 2022(1)

 

 

4,417

 

 

$

40.46

 

Expected to vest as of June 30, 2022(4)

 

 

3,701

 

 

$

40.22

 

 

(1)
Includes 1,378,708 and 913,388 performance-based restricted stock units as of June 30, 2022 and December 31, 2021, respectively, which represents the maximum amount that can vest.
(2)
Includes 559,430 performance-based restricted stock units.
(3)
Includes 94,110 performance-based restricted stock units
(4)
Includes 744,382 performance-based restricted stock units.

The total vesting date fair value of restricted stock units which vested during the three months ended June 30, 2022 and 2021 was $1.1 million and $1.9 million, respectively. The total vesting date fair value of restricted stock units which vested during the six months ended June 30, 2022 and 2021 was $33.5 million and $37.4 million, respectively.